[1] Siegel RL, Miller KD and Jemal A. Cancer statistics, 2019. CA Cancer J Clin 2019; 69: 7-34.
[2] Xiao L, Tien JC, Vo J, Tan M, Parolia A, Zhang Y, Wang L, Qiao Y, Shukla S, Wang X, Zheng H, Su F, Jing X, Luo E, Delekta A, Juckette KM, Xu A, Cao X, Alva AS, Kim Y, MacLeod AR and Chinnaiyan AM. Epigenetic Reprogramming with Antisense Oligonucleotides Enhances the Effectiveness of Androgen Receptor Inhibition in Castration-Resistant Prostate Cancer. Cancer Res 2018; 78: 5731-5740.
[3] Boccaletto P, Machnicka MA, Purta E, Piatkowski P, Baginski B, Wirecki TK, de Crécy-Lagard V, Ross R, Limbach PA, Kotter A, Helm M and Bujnicki JM. MODOMICS: a database of RNA modification pathways. 2017 update. Nucleic Acids Res 2018; 46: D303-d307.
[4] Cantara WA, Crain PF, Rozenski J, McCloskey JA, Harris KA, Zhang X, Vendeix FA, Fabris D and Agris PF. The RNA Modification Database, RNAMDB: 2011 update. Nucleic Acids Res 2011; 39: D195-201.
[5] Meyer KD, Saletore Y, Zumbo P, Elemento O, Mason CE and Jaffrey SR. Comprehensive analysis of mRNA methylation reveals enrichment in 3' UTRs and near stop codons. Cell 2012; 149: 1635-1646.
[6] Dubin DT and Taylor RH. The methylation state of poly A-containing messenger RNA from cultured hamster cells. Nucleic Acids Res 1975; 2: 1653-1668.
[7] Maity A and Das B. N6-methyladenosine modification in mRNA: machinery, function and implications for health and diseases. Febs j 2016; 283: 1607-1630.
[8] Tuncel G and Kalkan R. Importance of m N(6)-methyladenosine (m(6)A) RNA modification in cancer. Med Oncol 2019; 36: 36.
[9] Lin S, Choe J, Du P, Triboulet R and Gregory RI. The m(6)A Methyltransferase METTL3 Promotes Translation in Human Cancer Cells. Mol Cell 2016; 62: 335-345.
[10] Ma XX, Cao ZG and Zhao SL. m6A methyltransferase METTL3 promotes the progression of prostate cancer via m6A-modified LEF1. Eur Rev Med Pharmacol Sci 2020; 24: 3565-3571.
[11] Yuan Y, Du Y, Wang L and Liu X. The M6A methyltransferase METTL3 promotes the development and progression of prostate carcinoma via mediating MYC methylation. J Cancer 2020; 11: 3588-3595.
[12] Li E, Wei B, Wang X and Kang R. METTL3 enhances cell adhesion through stabilizing integrin β1 mRNA via an m6A-HuR-dependent mechanism in prostatic carcinoma. Am J Cancer Res 2020; 10: 1012-1025.
[13] Cotter KA, Gallon J, Uebersax N, Rubin P, Meyer KD, Piscuoglio S, Jaffrey SR and Rubin MA. Mapping of m6A and Its Regulatory Targets in Prostate Cancer Reveals a METTL3-low Induction of Therapy Resistance. Mol Cancer Res 2021;
[14] Du C, Lv C, Feng Y and Yu S. Activation of the KDM5A/miRNA-495/YTHDF2/m6A-MOB3B axis facilitates prostate cancer progression. J Exp Clin Cancer Res 2020; 39: 223.
[15] Li J, Xie H, Ying Y, Chen H, Yan H, He L, Xu M, Xu X, Liang Z, Liu B, Wang X, Zheng X and Xie L. YTHDF2 mediates the mRNA degradation of the tumor suppressors to induce AKT phosphorylation in N6-methyladenosine-dependent way in prostate cancer. Mol Cancer 2020; 19: 152.
[16] Zhu K, Li Y and Xu Y. The FTO m(6)A demethylase inhibits the invasion and migration of prostate cancer cells by regulating total m(6)A levels. Life Sci 2021; 271: 119180.
[17] Chen DS and Mellman I. Elements of cancer immunity and the cancer-immune set point. Nature 2017; 541: 321-330.
[18] Hänzelmann S, Castelo R and Guinney J. GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinformatics 2013; 14: 7.
[19] Zhang B, Wu Q, Li B, Wang D, Wang L and Zhou YL. m(6)A regulator-mediated methylation modification patterns and tumor microenvironment infiltration characterization in gastric cancer. Mol Cancer 2020; 19: 53.
[20] Quan Y, Cui Y, Wahafu W, Liu Y, Ping H and Zhang X. MLL5α activates AR/NDRG1 signaling to suppress prostate cancer progression. Am J Cancer Res 2020; 10: 1608-1629.
[21] Quan Y, Zhang X, Butler W, Du Z, Wang M, Liu Y and Ping H. The role of N-cadherin/c-Jun/NDRG1 axis in the progression of prostate cancer. International Journal of Biological Sciences 2021; 17: 3288-3304.
[22] Eggener SE, Scardino PT, Walsh PC, Han M, Partin AW, Trock BJ, Feng Z, Wood DP, Eastham JA, Yossepowitch O, Rabah DM, Kattan MW, Yu C, Klein EA and Stephenson AJ. Predicting 15-year prostate cancer specific mortality after radical prostatectomy. J Urol 2011; 185: 869-875.
[23] Kozminski MA, Tomlins S, Cole A, Singhal U, Lu L, Skolarus TA, Palapattu GS, Montgomery JS, Weizer AZ, Mehra R, Hollenbeck BK, Miller DC, He C, Feng FY and Morgan TM. Standardizing the definition of adverse pathology for lower risk men undergoing radical prostatectomy. Urol Oncol 2016; 34: 415 e411-416.
[24] Deek MP, Van der Eecken K, Phillips R, Parikh NR, Isaacsson Velho P, Lotan TL, Kishan AU, Maurer T, Boutros PC, Hovens C, Abramowtiz M, Pollack A, Desai N, Stish B, Feng FY, Eisenberger M, Carducci M, Pienta KJ, Markowski M, Paller CJ, Antonarakis ES, Berlin A, Ost P and Tran PT. The Mutational Landscape of Metastatic Castration-sensitive Prostate Cancer: The Spectrum Theory Revisited. Eur Urol 2021;
[25] Van Neste L, Groskopf J, Grizzle WE, Adams GW, DeGuenther MS, Kolettis PN, Bryant JE, Kearney GP, Kearney MC, Van Criekinge W and Gaston SM. Epigenetic risk score improves prostate cancer risk assessment. Prostate 2017; 77: 1259-1264.
[26] Natesan R, Aras S, Effron SS and Asangani IA. Epigenetic Regulation of Chromatin in Prostate Cancer. Adv Exp Med Biol 2019; 1210: 379-407.
[27] Desrosiers R, Friderici K and Rottman F. Identification of methylated nucleosides in messenger RNA from Novikoff hepatoma cells. Proc Natl Acad Sci U S A 1974; 71: 3971-3975.
[28] Alarcón CR, Lee H, Goodarzi H, Halberg N and Tavazoie SF. N6-methyladenosine marks primary microRNAs for processing. Nature 2015; 519: 482-485.
[29] Patil DP, Chen CK, Pickering BF, Chow A, Jackson C, Guttman M and Jaffrey SR. m(6)A RNA methylation promotes XIST-mediated transcriptional repression. Nature 2016; 537: 369-373.
[30] Chen Y, Pan C, Wang X, Xu D, Ma Y, Hu J, Chen P, Xiang Z, Rao Q and Han X. Silencing of METTL3 effectively hinders invasion and metastasis of prostate cancer cells. Theranostics 2021; 11: 7640-7657.
[31] Li J, Xie H, Ying Y, Chen H, Yan H, He L, Xu M, Xu X, Liang Z, Liu B, Wang X, Zheng X and Xie L. YTHDF2 mediates the mRNA degradation of the tumor suppressors to induce AKT phosphorylation in N6-methyladenosine-dependent way in prostate cancer. Molecular cancer 2020; 19: 152-152.
[32] Cotter KA, Gallon J, Uebersax N, Rubin P, Meyer KD, Piscuoglio S, Jaffrey SR and Rubin MA. Mapping of m(6)A and Its Regulatory Targets in Prostate Cancer Reveals a METTL3-Low Induction of Therapy Resistance. Mol Cancer Res 2021; 19: 1398-1411.
[33] Zhao Y, Sun H, Zheng J and Shao C. Analysis of RNA m(6)A methylation regulators and tumour immune cell infiltration characterization in prostate cancer. Artif Cells Nanomed Biotechnol 2021; 49: 407-435.
[34] Zhang Q, Luan J, Song L, Wei X, Xia J and Song N. Malignant Evaluation and Clinical Prognostic Values of M6A RNA Methylation Regulators in Prostate Cancer. J Cancer 2021; 12: 3575-3586.
[35] Ji G, Huang C, He S, Gong Y, Song G, Li X and Zhou L. Comprehensive analysis of m6A regulators prognostic value in prostate cancer. Aging (Albany NY) 2020; 12: 14863-14884.
[36] Ou-Yang S, Liu JH and Wang QZ. Expression patterns and a prognostic model of m(6)A-associated regulators in prostate adenocarcinoma. Biomark Med 2020; 14: 1663-1677.
[37] Wang J, Lin H, Zhou M, Xiang Q, Deng Y, Luo L, Liu Y, Zhu Z and Zhao Z. The m6A methylation regulator-based signature for predicting the prognosis of prostate cancer. Future Oncol 2020; 16: 2421-2432.
[38] Wu Q, Xie X, Huang Y, Meng S, Li Y, Wang H and Hu Y. N6-methyladenosine RNA methylation regulators contribute to the progression of prostate cancer. J Cancer 2021; 12: 682-692.
[39] Liu B, Jiang HY, Yuan T, Luo J, Zhou WD, Jiang QQ and Wu D. Enzalutamide-Induced Upregulation of PCAT6 Promotes Prostate Cancer Neuroendocrine Differentiation by Regulating miR-326/HNRNPA2B1 Axis. Front Oncol 2021; 11: 650054.
[40] Jiang M, Lu Y, Duan D, Wang H, Man G, Kang C, Abulimiti K and Li Y. Systematic Investigation of mRNA N (6)-Methyladenosine Machinery in Primary Prostate Cancer. Dis Markers 2020; 2020: 8833438.
[41] Cheng Y, Li L, Qin Z, Li X and Qi F. Identification of castration-resistant prostate cancer-related hub genes using weighted gene co-expression network analysis. J Cell Mol Med 2020; 24: 8006-8017.
[42] Singh AN and Sharma N. Quantitative SWATH-Based Proteomic Profiling for Identification of Mechanism-Driven Diagnostic Biomarkers Conferring in the Progression of Metastatic Prostate Cancer. Front Oncol 2020; 10: 493.
[43] Peng Z, Andersson K, Lindholm J, Dethlefsen O, Pramana S, Pawitan Y, Nistér M, Nilsson S and Li C. Improving the Prediction of Prostate Cancer Overall Survival by Supplementing Readily Available Clinical Data with Gene Expression Levels of IGFBP3 and F3 in Formalin-Fixed Paraffin Embedded Core Needle Biopsy Material. PLoS One 2016; 11: e0145545.
[44] Prager AJ, Peng CR, Lita E, McNally D, Kaushal A, Sproull M, Compton K, Dahut WL, Figg WD, Citrin D and Camphausen KA. Urinary aHGF, IGFBP3 and OPN as diagnostic and prognostic biomarkers for prostate cancer. Biomarkers in medicine 2013; 7: 831-841.
[45] Qie Y, Nian X, Liu X, Hu H, Zhang C, Xie L, Han R, Wu C and Xu Y. Polymorphism in IGFBP3 gene is associated with prostate cancer risk: an updated meta-analysis. OncoTargets and therapy 2016; 9: 4163-4171.
[46] Zhang X, Wang D, Liu B, Jin X, Wang X, Pan J, Tu W and Shao Y. IMP3 accelerates the progression of prostate cancer through inhibiting PTEN expression in a SMURF1-dependent way. J Exp Clin Cancer Res 2020; 39: 190.
[47] Szarvas T, Tschirdewahn S, Niedworok C, Kramer G, Sevcenco S, Reis H, Shariat SF, Rübben H and vom Dorp F. Prognostic value of tissue and circulating levels of IMP3 in prostate cancer. Int J Cancer 2014; 135: 1596-1604.
[48] Ikenberg K, Fritzsche FR, Zuerrer-Haerdi U, Hofmann I, Hermanns T, Seifert H, Müntener M, Provenzano M, Sulser T, Behnke S, Gerhardt J, Mortezavi A, Wild P, Hofstädter F, Burger M, Moch H and Kristiansen G. Insulin-like growth factor II mRNA binding protein 3 (IMP3) is overexpressed in prostate cancer and correlates with higher Gleason scores. BMC Cancer 2010; 10: 341.
[49] Binnewies M, Roberts EW, Kersten K, Chan V, Fearon DF, Merad M, Coussens LM, Gabrilovich DI, Ostrand-Rosenberg S, Hedrick CC, Vonderheide RH, Pittet MJ, Jain RK, Zou W, Howcroft TK, Woodhouse EC, Weinberg RA and Krummel MF. Understanding the tumor immune microenvironment (TIME) for effective therapy. Nat Med 2018; 24: 541-550.
[50] Quail DF and Joyce JA. Microenvironmental regulation of tumor progression and metastasis. Nat Med 2013; 19: 1423-1437.